Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has been assigned an average rating of "Buy" from the seven brokerages that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $20.50.
A number of equities analysts recently commented on the company. Jones Trading upgraded Protara Therapeutics to a "strong-buy" rating and set a $21.00 price target for the company in a report on Thursday, May 22nd. HC Wainwright reiterated a "buy" rating and set a $23.00 price target on shares of Protara Therapeutics in a report on Monday, April 28th. Finally, Scotiabank assumed coverage on Protara Therapeutics in a report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 price target for the company.
Read Our Latest Stock Report on Protara Therapeutics
Institutional Investors Weigh In On Protara Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. bought a new position in Protara Therapeutics in the 1st quarter valued at $64,000. HBK Investments L P bought a new position in Protara Therapeutics in the 4th quarter valued at $106,000. Squarepoint Ops LLC bought a new position in Protara Therapeutics in the 4th quarter valued at $110,000. Dimensional Fund Advisors LP bought a new position in Protara Therapeutics in the 4th quarter valued at $111,000. Finally, American Century Companies Inc. bought a new position in Protara Therapeutics in the 1st quarter valued at $154,000. Institutional investors and hedge funds own 38.13% of the company's stock.
Protara Therapeutics Price Performance
Shares of TARA traded down $0.01 during midday trading on Friday, hitting $3.33. The stock had a trading volume of 111,494 shares, compared to its average volume of 446,983. The company has a 50 day simple moving average of $3.13 and a two-hundred day simple moving average of $3.79. Protara Therapeutics has a twelve month low of $1.60 and a twelve month high of $10.48. The firm has a market cap of $128.47 million, a price-to-earnings ratio of -1.94 and a beta of 1.35.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.18. Analysts forecast that Protara Therapeutics will post -3.32 EPS for the current fiscal year.
Protara Therapeutics Company Profile
(
Get Free ReportProtara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Read More
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
